pegcetacoplan news

All news on pegcetacoplan (also known as Empaveli): plants, production capacities, investments and involved companies.

24 August 2026

Sobi Japan and Asahi Kasei: Empaveli approved in Japan for C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis

First complement inhibitor in Japan for patients aged 12+ with these rare kidney diseases; VALIANT showed 68.1% proteinuria reduction and eGFR stabilization versus placebo.

Who will be producing pegcetacoplan in the future?

Find out with chemXplore Alpha

Learn more